NCT02151344: Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals |
|
|
| Completed | 1 | 100 | US | H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Influenza A Virus, H7N9 Subtype | 02/15 | 02/15 | | |
NCT01995695: Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults |
|
|
| Completed | 1 | 48 | US | Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine | National Institute of Allergy and Infectious Diseases (NIAID), University of Rochester | Influenza A Virus, H7N9 Subtype | 01/16 | | | |
NCT02274545: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old |
|
|
| Completed | 1 | 24 | US | H7N9 Anhui 2013/AA ca, H7N9 (6-2) AA ca recombinant vaccine, A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca, H7N9 A/Anhui/13 ca pLAIV, Inactivated subvirion H7N9 vaccine, H7N9 pIIV | National Institute of Allergy and Infectious Diseases (NIAID) | Influenza A Virus, H7N9 Subtype | 05/16 | | | |
